Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period ActivityBusiness Wire • 08/03/23
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth ConferenceBusiness Wire • 08/02/23
Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development TimelineSeeking Alpha • 07/30/23
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular RiskBusiness Wire • 07/24/23
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/20/23
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial ResultsBusiness Wire • 07/20/23
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of MedicineBusiness Wire • 07/19/23
BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart DiseaseInvestors Business Daily • 07/17/23
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer's Disease and Cerebral Amyloid AngiopathyBusiness Wire • 07/17/23
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 06/30/23
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare ConferenceBusiness Wire • 06/05/23
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with CardiomyopathyBusiness Wire • 05/20/23
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period ActivityBusiness Wire • 05/04/23
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care ConferenceBusiness Wire • 05/03/23